Literature DB >> 18160418

Paediatric systemic lupus erythematosus: prognostic impact of antiphospholipid antibodies.

E Descloux1, I Durieu, P Cochat, D Vital Durand, J Ninet, N Fabien, R Cimaz.   

Abstract

OBJECTIVES: The aim of our study was to investigate the prognostic impact of aPL in paediatric onset systemic lupus erythematosus (p-SLE).
METHODS: This retrospective study included 56 patients with p-SLE. Chi2-test, Fisher's exact test, incidence rate ratio and Kaplan-Meier survival curves were used to compare aPL-positive and aPL-negative patients considering the value of SDI (Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index for SLE) at the end of follow-up, the occurrence of thromboses, organ system involvements and need for immunosuppressive treatment in addition to corticosteroids.
RESULTS: Anti-cardiolipin antibodies and lupus anticoagulants were detected in 27 (49%) and 19 (35%) patients, respectively. These aPL were frequently transient or intermittent (10 and 15 cases, respectively), and only rarely persistent over time (five cases). The risk of thrombosis was significantly higher (odds ratio = 6.42) and occurred earlier in the presence of aPL, especially if aPL were persistent (P < 0.05). The association between aPL and neurological, renal, haematological manifestations or need for immunosuppressive treatment was not statistically significant. After a mean follow-up of 7.2 yrs, 30 patients (54.5%) had an SDI score > or = 1. The risk of damage (SDI > or = 1) in aPL-positive patients was three times higher than in aPL-negative patients (P < 0.05). Four of the six fatal cases occurred in the aPL-positive group.
CONCLUSIONS: The presence of aPL in p-SLE could represent not only a risk factor for thrombosis but also a poor prognostic factor overall.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18160418     DOI: 10.1093/rheumatology/kem335

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  11 in total

1.  Pediatric lupus--are there differences in presentation, genetics, response to therapy, and damage accrual compared with adult lupus?

Authors:  Rina Mina; Hermine I Brunner
Journal:  Rheum Dis Clin North Am       Date:  2010-02       Impact factor: 2.670

Review 2.  Prevalence and burden of pediatric-onset systemic lupus erythematosus.

Authors:  Sylvia Kamphuis; Earl D Silverman
Journal:  Nat Rev Rheumatol       Date:  2010-08-03       Impact factor: 20.543

Review 3.  Pediatric antiphospholipid syndrome.

Authors:  Jacqueline A Madison; Yu Zuo; Jason S Knight
Journal:  Eur J Rheumatol       Date:  2019-12-03

4.  The thrombophilic network of autoantibodies in celiac disease.

Authors:  Aaron Lerner; Nancy Agmon-Levin; Yinon Shapira; Boris Gilburd; Sandra Reuter; Idit Lavi; Yehuda Shoenfeld
Journal:  BMC Med       Date:  2013-04-04       Impact factor: 8.775

Review 5.  Pediatric Antiphospholipid Syndrome: from Pathogenesis to Clinical Management.

Authors:  Silvia Rosina; Cecilia Beatrice Chighizola; Angelo Ravelli; Rolando Cimaz
Journal:  Curr Rheumatol Rep       Date:  2021-01-28       Impact factor: 4.592

6.  Prognostic Factors at Diagnosis Associated With Damage Accrual in Childhood-Onset Systemic Lupus Erythematosus Patients.

Authors:  Ana Luisa Rodríguez-Lozano; Francisco Eduardo Rivas-Larrauri; Silvestre García-de la Puente; Daniel Alfredo Alcivar-Arteaga; Alejandro Gabriel González-Garay
Journal:  Front Pediatr       Date:  2022-04-22       Impact factor: 3.418

7.  Lipid anti-lipid antibody responses correlate with disease activity in systemic lupus erythematosus.

Authors:  Vojislav Jovanović; Nurhuda Abdul Aziz; Yan Ting Lim; Amanda Ng Ai Poh; Sherlynn Jin Hui Chan; Eliza Ho Xin Pei; Fei Chuin Lew; Guanghou Shui; Andrew M Jenner; Li Bowen; Eoin F McKinney; Paul A Lyons; Michael D Kemeny; Kenneth G C Smith; Markus R Wenk; Paul A Macary
Journal:  PLoS One       Date:  2013-02-07       Impact factor: 3.240

8.  An unusual presentation of lupus in a pediatric patient.

Authors:  Vimal Master Sankar Raj
Journal:  Case Rep Pediatr       Date:  2013-08-27

9.  Morbidity and Mortality in Iranian Children with Juvenile Systemic Lupus erythematosus.

Authors:  Fariba Tavangar-Rad; Vahid Ziaee; Mohammad-Hassan Moradinejad; Fatemeh Tahghighi
Journal:  Iran J Pediatr       Date:  2014-07-01       Impact factor: 0.364

10.  The impact of antiphospholipid antibodies in children with lupus nephritis.

Authors:  Sulaiman M Al-Mayouf; Alhanouf AlSaleem; Turki Al-Hussain; Abdullah Al Sonbul; Hadeel AlMana
Journal:  Int J Pediatr Adolesc Med       Date:  2015-11-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.